We have collected information about Rational Design Of Cationic Lipids For Sirna Delivery for you. Follow the links to find out details on Rational Design Of Cationic Lipids For Sirna Delivery.
https://www.nature.com/articles/nbt.1602
Jan 17, 2010 · Two important parameters underlying lipid design for SNALP-mediated delivery are the pK a of the ionizable cationic lipid and the abilities of these lipids, when protonated, to …Author: Sean C Semple, Akin Akinc, Jianxin Chen, Ammen P Sandhu, Barbara L Mui, Connie K Cho, Dinah W Y Sah,...
https://www.ncbi.nlm.nih.gov/pubmed/20081866
We adopted a rational approach to design cationic lipids for use in formulations to deliver small interfering RNA (siRNA). Starting with the ionizable cationic lipid 1,2-dilinoleyloxy-3-dimethylaminopropane (DLinDMA), a key lipid component of stable nucleic acid lipid particles (SNALP) as a benchmark, we used the proposed in vivo mechanism of action of ionizable cationic lipids to guide the design of DLinDMA-based lipids …Author: Sean C Semple, Akin Akinc, Jianxin Chen, Ammen P Sandhu, Barbara L Mui, Connie K Cho, Dinah W Y Sah,...
http://arbutusbio.com/docs/Semple_et_al_2010.pdf
We adopted a rational approach to design cationic lipids for use in formulations to deliver small interfering RNA (siRNA). Starting with the ionizable cationic lipid 1,2-dilinoleyloxy-3- dimethylaminopropane (DLinDMA), a key lipid component of
https://media.nature.com/original/nature-assets/nbt/journal/v28/n2/extref/nbt.1602-S1.pdf
Novel Cationic Lipids Semple, S., Akinc, A, Chen J, et al. Rational design of novel cationic lipids for use in next-generation siRNA delivery systems . Supplementary Table 1. Linker modifications to DLinDMA . Abbreviated Name Chemical Name Structure Mean Particle Size (nm)a ED 50 (mg/kg) DLinDMA (Benchmark) 1,2-Dilinoleyloxy-3-dimethylaminopropane
https://www.sciencedirect.com/science/article/pii/S0168365911010364
The development of siRNA delivery systems which can overcome these limitations has been the subject of intense recent focus , , , , . Cationic lipids have three general structural components: the cationic head group, the lipid tail(s), and the linkers that connect the two.Author: Jeff Sparks, Gregory Slobodkin, Majed Matar, Richard Congo, David Ulkoski, Angela Rea-Ramsey, Casey ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4060977/
Nov 10, 2013 · The complexation of cationic lipids with siRNA was investigated utilizing dynamic light scattering (DLS) and a RiboGreen fluorescence-based assay that can detect free, non-encapsulated RNA. Nanoparticle formation was observed when both the lipids and siRNA were mixed together at N/P ratios above 1.0, as determined by the RiboGreen assay (data ...Author: Anthony S. Malamas, Maneesh Gujrati, China M. Kummitha, Rongzuo Xu, Zheng Rong Lu
https://www.nature.com/articles/nmat3765
Oct 23, 2013 · Therapeutics based on small interfering RNA (siRNA), which in principle are able to reversibly silence any gene of interest, are under development for the …Author: Rosemary Kanasty, Joseph Robert Dorkin, Arturo Vegas, Arturo Vegas, Daniel Anderson
https://www.precisionnanosystems.com/resource-center/publications/detail/nose-to-brain-delivery-of-enveloped-rna---cell-permeating-peptide-nanocomplexes-for-the-treatment-of-neurodegenerative-diseases
Direct nose-to-brain (N-to-B) delivery enables the rapid transport of drugs to the brain, while minimizing systemic exposure. The objective of this work was to engineer a nanocarrier intended to enhance N-to-B delivery of RNA and to explore its potential utility for the treatment of neurological disorders. Our approach involved the formation of electrostatically driven nanocomplexes between a ...
https://www.sciencedirect.com/science/article/pii/S0169409X20300193
Apr 01, 2020 · Optimizing synthetic nanocarriers is like searching for a needle in a haystack. How to find the most suitable carrier for intracellular delivery of a …
https://www.cell.com/molecular-therapy-family/nucleic-acids/fulltext/S2162-2531(19)30017-4
Despite progress made over the past several years, there remains significant opportunity for improvement, as the most advanced LNPs were designed for intravenous (IV) delivery of siRNA to the liver.Author: Kimberly J. Hassett, Kerry E. Benenato, Eric Jacquinet, Aisha Lee, Angela Woods, Olga Yuzhakov, Sunn...
Searching for Rational Design Of Cationic Lipids For Sirna Delivery?
You can just click the links above. The data is collected for you.
